Business model for sustainable growth
BioGaia has two types of distribution – via our distribution partners and direct distribution. The majority of BioGaia’s revenue comes from gut health products, such as chewable tablets, drops for children with colic, and oral health products. Revenue is also earned from the sale of bacterial cultures to be used in licensees’ products (such as infant formula and dairy products), as well as royalties for the use of L. reuteri in licensees’ products. BioGaia’s products are available in more than 100 markets through sales via nutrition and pharmaceutical companies and our own subsidiaries.
To date, more than 250 clinical studies using BioGaia’s human strains of L. reuteri have been performed on about 21,000 individuals of all ages (dec 2021).
BioGaia has a strong network of distribution partners around the globe. Most of the around 80 partners are pharmaceutical or other health companies.
BioGaia’s products are sold in around 100 countries. The largest segment is paediatrics, accounting for over 80 per cent of total sales.